Preprint
Article
Primary Series COVID-19 Vaccine Effectiveness among Health Care Workers in the Country of Georgia, March–December 2021
Altmetrics
Downloads
187
Views
133
Comments
1
A peer-reviewed article of this preprint also exists.
supplementary.xlsx (31.48KB )
This version is not peer-reviewed
Preprints on COVID-19 and SARS-CoV-2
Submitted:
05 October 2023
Posted:
07 October 2023
You are already at the latest version
Alerts
Abstract
Background Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19 pandemic. Few data on COVID-19 vaccine effectiveness (VE) are available from middle-income countries in Europe. We evaluated primary series COVID-19 VE against laboratory-confirmed COVID-19 among HCWs in Georgia. Methods HCWs in six hospitals in Georgia were invited to enroll in a prospective cohort study conducted during March 19–December 5, 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT), and participants were routinely tested for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected at enrolment, and quarterly thereafter, and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We defined primary series vaccination as two doses of COVID-19 vaccine received ≥14 days before symptom onset. We estimated VE as (1-hazard ratio)*100 using a Cox proportional hazards model with vaccination status as a time-varying covariate. Estimates were adjusted by potential confounders that changed the VE estimate by more than 5%, according to the change-in-estimate approach. Results Overall, 1561/3849 (41%) eligible HCWs enrolled and were included in the analysis. The median age was 40 (IQR: 30-53), 1318 (84%) were female, and 1003 (64%) had laboratory evidence of prior SARS-Cov-2 infection. At enrolment, 1300 (83%) were unvaccinated; By study end, 1082 (62%) had completed a primary vaccine series (69% BNT162b2 (Pfizer-BioNTech); 22% BBIBP-CorV (Sinopharm); 9% other). During the study period, 191(12%) participants had a new PCR- or RAT-confirmed symptomatic SARS-CoV-2 infection. VEa gainst PCR- or RAT- confirmed symptomatic SARS-CoV-2 infection was 58 (95%CI: 41; 70) for all primary series vaccinations, 68% (95%CI: 51; 79) for BNT162b2, and 40% (95%CI: 1; 64) for BBIBP-CorV vaccines. Among previously infected HCWs, VE was 58% (95%CI: 11; 80). VE against medically attended COVID-19 was 52% (95%CI: 28; 68), and VE against hospitalization was 69% (95% CI: 36; 85). During the period of predominant Delta variant circulation (July-December 2021), VE against symptomatic COVID-19 was 52% (95%CI: 30; 66). Conclusions Primary series vaccination with BNT162b2 and BBIBP-CorV was effective at preventing COVID-19 among HCWs, most of whom had previous infection, during a period of mainly Delta circulation. Our results support the utility of COVID-19 primary vaccine series, and the importance of increasing coverage, even among previously infected individuals.
Keywords:
Subject: Public Health and Healthcare - Public, Environmental and Occupational Health
Introduction
Health care workers (HCWs) have suffered high rates of morbidity and mortality during the COVID-19 pandemic.[1] Limiting SARS-CoV-2 infections among HCWs is critical to ensure the presence of an adequate healthcare workforce to respond to routine and pandemic-related demands, a challenge that is magnified in resource-poor healthcare systems in low- and middle-income countries (LMICs).[2]
COVID-19 vaccine has been a critical intervention to reduce both morbidity and mortality during the pandemic. Since late 2020, when global vaccine distribution began, nearly 13.5 billion COVID-19 vaccine doses have been administered worldwide.[3] In the first year after their introduction, COVID-19 vaccines were estimated to have saved nearly 20 million lives globally,[4] and over 440,000 lives among persons ≥ 60 years old in Europe. [5]
Understanding COVID-19 vaccine effectiveness is critical to inform national and international vaccination guidelines. However, despite the extensive use of COVID-19 vaccines in LMICs, few VE studies have been conducted in LMICs. In the WHO European Region , where 20 of the 53 member countries are middle-income countries (MICs) [6], most VE studies to date have been conducted in high-income countries (HICs). [7] Differences in population-level demographics and comorbidities in MICs compared to HICs could potentially lead to differences in overall vaccine performance. In addition, MICs in the WHO European Region have used a broader variety of COVID -19 vaccine products compared to HICs, including inactivated virus vaccines. [8] In the WHO European Region, primary series COVID -19 vaccine coverage has been considerably lower in MICs compared to HICs; as of 4 August 2023, primary series COVID -19 vaccine coverage was 73.8% and booster dose coverage was 48.4% in HICs compared to 55.3% and 15.9%, respectively, in upper MICs. [9] Having local data on COVID-19 VE from MICs in the WHO European Region could provide the additional advantage of promoting increased vaccine uptake.
In Georgia, an upper-middle income country of 3.7 million people, the COVID-19 vaccine rollout began on 15 March 2021 [10]. For the initial vaccine rollout, both ChAdOx1-S vaccine (Oxford/AstraZeneca) and BNT162b2 vaccine (Pfizer-BioNTech) were procured via the COVAX facility mechanism. Later in 2021, BBIBP-CorV vaccine (Sinopharm), CoronaVac vaccine (Sinovac Life Sciences, Beijing, China), and additional BNT162b2 vaccines were procured independently by the government of Georgia. HCWs were among the initial priority groups for vaccination. We conducted a prospective cohort study of COVID-19 VE among HCWs in six hospitals in Georgia. Here we describe the results of the initial interim analysis (March–December, 2021).
Materials and methods
Study Design
We conducted a prospective cohort study to evaluate VE against symptomatic SARS-CoV-2 infection among HCWs in six hospitals in Georgia. The study design was based on a VE guidance document published by the WHO Regional Office for Europe, [11] and the study was conducted within the framework of WHO’s Unity platform. [12]
Data Collection and Management
From 19 March–16 July 2021, we invited all HCWs ≥ 18 years old who were employed at the study hospitals and eligible to receive the COVID-19 vaccine to participate in the study, as previously described.10 At the time of enrolment, contra-indications to the COVID-19 vaccine in Georgia included having had a SARS-CoV-2 infection in the previous 120 days, and having an acute febrile illness at the time of intended vaccination. HCWs could participate in the study regardless of their hospital role, prior infection status, or their intention to receive COVID-19 vaccine. All HCWs in the study received COVID-19 through the national vaccine campaign led by the Georgia Ministry of Health.
At enrolment, participants completed a questionnaire that included questions about socio-demographics, comorbidities, occupation, self-perceived health status, prior SARS-CoV-2 infection, and COVID-19 and influenza vaccination history. In addition, at enrolment, every participant provided a blood sample for serology testing.
Following enrolment, participants completed a weekly symptom questionnaire, administered by study personnel; participants who reported any symptoms included in the Georgia MoH suspected COVID-19 case definition (fever, cough, general weakness, fatigue, headache, muscle aches, sore throat, runny nose, shortness of breath, lack of appetite, nausea, vomiting, diarrhea, altered mental status, loss of taste, or loss of smell) provided a respiratory specimen, which was tested for SARS-CoV-2 by either RT-PCR or rapid antigen test (RAT), depending on availability at each facility. In addition, during the entire study period, HCWs at all six hospitals could be tested routinely for SARS-CoV-2 by RT-PCR or RATs.
RT-PCR-positive samples were sent to the Richard G. Lugar Center for Public Health Research in Tbilisi, Georgia, where they underwent whole genome sequencing. Study staff verified participants’ vaccination status through the National Immunization Registry and confirmed RT-PCR and RAT results through the national SARS-CoV-2 laboratory database. Participants who tested positive for SARS-CoV-2 by RT- PCR or RAT were administered a follow-up questionnaire 30 days after their positive test, which included additional questions about symptoms and medical care. All study data were entered securely and stored in REDCap. [13]
Serology
Phlebotomists collected serology specimens from participants at enrolment, and three and six months after enrolment. Serology samples were tested for anti-nucleocapsid antibodies and anti-spike antibodies by Roche Elecsys Anti-SARS-CoV-2 S immunoassay electrochemiluminescence immunoassay (ECLIA). [14] For both serological assays, cutoff values were determined according to instructions from the package insert.
Vaccine effectiveness analysis
For our primary outcome, because RAT testing occurred frequently and was not always accompanied by a PCR test, we measured primary series VE against a combined outcome of PCR-confirmed SARS-CoV-2 infection and/or RAT-confirmed COVID-19, which we defined as a positive test result in a participant who had symptom onset from 14 days before until four days after the date of specimen collection. Participants were considered fully vaccinated with their primary series ≥14 days after receipt of their second COVID-19 vaccine.
We conducted VE analyses for all primary series vaccination and then separately for primary series BNT162b2 and primary series BBIBP-CorV against outcomes of symptomatic infection, medically attended infection, and hospitalization. We also evaluated VE separately for the period in which SARS-CoV-2 B.1.617.2 (Delta variant) was predominant (5 July 2021 -– 5 December 2021), which we defined using sequencing data from study samples along with publicly available data from Georgia in the Global Initiative on Sharing All Influenza Data (GISAID). [15]
We also evaluated the combined effect of prior SARS-CoV-2 infection and COVID-19 vaccination on VE, using unvaccinated participants without prior infection as the category of reference. For the primary analysis, participants were considered to have had prior SARS-CoV-2 infection if they reported previous PCR-confirmed and/or RAT-confirmed infection and/or were seropositive for anti-nucleocapsid antibody at enrolment. For participants who received inactivated virus vaccine more than 5 days prior to enrolment, we defined prior infection by PCR and RAT only.
In addition, we measured primary series VE against both symptomatic and asymptomatic SARS-CoV-2 infection, measured by a combined endpoint of a PCR-positive test, a RAT-positive test, and/or seroconversion, which we defined as a positive three-month or six-month anti-nucleocapsid antibody test in a participant who was previously seronegative. For participants who seroconverted during the study but did not have symptomatic illness prior to their seroconversion, we estimated the time of asymptomatic infection as halfway between the last negative serological test and the subsequent positive serological test, taking into account a 3-week lag for seroconversion among asymptomatic persons. [16] For participants who had a symptomatic illness prior to their seroconversion, but did not have a positive PCR or RAT test, we assumed that the infection occurred on the date of onset of their symptomatic illness. For this analysis we only included participants who received BNT162b2 vaccine, as inactivated vaccines can generate the production of anti-nucleocapsid antibodies.
Further analyses and sensitivity analyses
We examined waning immunity by comparing VE in the periods from 14 – 89 days, 90 – 179 days and ≥180 days since the second vaccine dose, for both the overall period and the period of Delta circulation only.
Statistical model
VE was estimated as (1 – adjusted hazard ratio)*100. Hazard ratios (HRs) comparing vaccinated and unvaccinated were estimated using Cox proportional hazards models with vaccination as a time-varying exposure (vaccination status of some individuals changed over time from unvaccinated to vaccinated, and from one to two doses), which allowed participants to contribute person-time to more than one exposure category. Calendar time was used as the underlying time in the Cox regression.
We calculated unadjusted HR and used adjusted HR to estimate VE. Both estimates included hospital as a fixed effect. We adjusted the multivariable regression model using a priori fixed covariates (hospital, age, sex, prior SARS-CoV-2 infection) and considered potential confounders (role in hospital, hands-on care, face-to-face patient contact, smoking, household size, any comorbidity, body mass index [BMI] category, and self-perceived health status) that changed the VE estimate by more than 5%, according to the change-in-estimate approach. We used stratification to address violations of the proportional hazards assumption.
Participants with a SARS-CoV-2 infection prior to enrollment started contributing person-time when they were considered “at risk” of reinfection, which we defined as 90 days after their most recent positive PCR or RAT test or, for participants without who were seropositive at enrolment but did not have a history of a PCR- or RAT-positive test, four weeks after their positive enrolment serology.
Participants contributed person-time from enrolment, or from the start of time at risk for those with prior SARS-CoV-2 infection, until whichever of the following endpoints came first: 1) the day of the first SARS-CoV-2 infection, 2) the day of receipt of a third vaccine dose, or 3) the day of withdrawal from the study, or censor date for the analysis period (5 December 2021). Person-time of persons vaccinated with only one dose was excluded from all analyses from the day they received their first dose.
For all of the proposed analyses above, we only considered results from models that had achieved convergence and had a minimum of 5 events per category of vaccine status, ensuring our ability to construct reliable models.
Ethics and study registration
The study was approved by the NCDC and WHO Research Ethics Review Committees (reference numbers IRB 2021-014 and CERC.0097C, respectively). The CDC humans review determined the activity to be a public health evaluation. All participants provided written informed consent. The study is also registered at clinicaltrials.gov (Identifier NCT04868448).
Results
Of 3,849 HCWs working in the six hospitals, we enrolled 1592 (41%) participants, of whom 31 were excluded from the analysis for various reasons (Figure 1). Of the 1,561 HCWs included in the analysis, the median age was 40 (IQR: 30-53) and 1318 (84%) were female. Overall, 390 (25%) participants reported having at least one underlying chronic condition. Most HCWs were nurses or midwives [604 (39%)] and physicians [306 (20%)] (Table 1). Overall, 816 (52%) participants reported providing “hands-on care” to patients. Age and sex distribution, comorbid conditions, and occupation were similar across sites. Of the 1475 participants who were either unvaccinated at enrolment or received their first COVID-19 dose no more than 5 days prior to enrolment, 937 (63%) had evidence of prior infection by seropositivity for either anti-spike antibodies or anti-nucleocapsid antibodies.
At enrolment, 224 (14%) participants had already received one dose of COVID-19 vaccine, 37 (2%) participants had received two doses, and 1,300 (83%) participants were unvaccinated (Table 1). At the end of the follow-up period, 1082 (69%) participants had received two doses, and 479 (31%) participants remained unvaccinated (Table S1). Of the 1,082 participants who had received two vaccine doses by the end of the follow-up period, most [745 (69%)] received BNT162b2, while 238 (22%) received BBIBP-CorV, 58 (5%) received CoronaVac, 26 (2%) received ChAdOx1-S and 14 (1%) received heterologous vaccination (Table S1 and Figure 2). At the end of the analysis period, compared to participants who had received two doses of vaccine, unvaccinated participants were more likely to be doctors (24% vs. 10%) and were slightly younger (38 years [IQR = 28-52 vs. 41 years [IQR = 30-53]) but otherwise demographic, health, and occupation characteristics were similar between vaccinated and unvaccinated participants (Table S1).
During the study period, specimens were collected and tested from 686/796 (86%) reported symptomatic events. There were 124 symptomatic SARS-CoV-2 infections among unvaccinated participants (90 by PCR and 34 by RAT), and 67 symptomatic infections (52 by PCR and 15 by RAT) among participants who had completed a primary series (Table 2). Of the 191 symptomatic infections that occurred during the study period, 163 (85%) occurred between 1 July – 5 December 2021, a period during which the Delta variant predominated (Figure 3 and Figure S1).
All participants who were infected during the study period completed the 30-day follow up questionnaire after their positive PCR or RAT test; 132/191 (69%) sought medical care, 26/188 (14%) sought care at an emergency department, 44/191 (23%) were hospitalized, 12/191 were admitted to the ICU and no one died.
Primary series VE against the combined outcome of symptomatic PCR-confirmed and RAT-confirmed infections was 58% (95%CI: 41,70). Among participants without prior infection, aVE was 56% (95%CI: 35, 70), and among those with prior SARS-CoV-2 infection, aVE was 58% (95%CI: 11, 80) (Table 2). For participants who received primary series BNT162b2 vaccine, overall aVE was 68% (95%CI: 51, 79). In those without prior infection, primary series BNT162b2 aVE was 63% (95%CI: 43, 77) (Table 2 and Figure 4). For participants who received primary series BBIBP-CorV vaccine, overall aVE was 40% (95%CI: 1, 64). In those without prior infection, aVE for primary series BBIBP-CorV was 31% (95%CI: -26, 62) (Table 2).
Overall VE against medically attended PCR- and RAT-confirmed COVID-19 was 52% (95% CI: 28; 67), and VE against PCR- and RAT-confirmed hospitalizations was 69% (95% CI: 36; 85) (Table 3 and Figure 4). During the Delta-predominant period, VE against medically attended COVID-19 was 41% (95% CI: 10; 61), and aVE against hospitalization was 61% (95% CI: 13; 81). Overall, for BNT162b2, VE against medically attended COVID-19 was 63% (95% CI: 39; 78). Because of the low number of events, BNT162b2 aVE against hospitalization could not be calculated, and BBIBP-CorV aVe against medically attended COVID-19 and hospitalization could not be calculated.
Primary series VE estimates against symptomatic, PCR-confirmed SARS-CoV-2 infection, medically attended infection, and hospitalization were similar to aVE estimates for the combined PCR/RAT endpoint. (Table S2).
Compared to unvaccinated participants with no evidence of prior SARS-CoV-2 infection, aVE against symptomatic PCR- and RAT-confirmed infection was 56% (95%CI: 35; 70) for vaccinated participants without evidence of prior infection, and 95% (95%CI: 90; –98) for vaccinated participants who had prior infection. Protection against symptomatic, PCR- and RAT-confirmed infection was 85% (95%CI: 77; –90) for unvaccinated participants who had been previously infected. Trends were similar when we limited this analysis to BNT162b2-only, BBIBP-CorV-only, and for all vaccines for the Delta period (Table 4).
In our evaluation of protection against the more inclusive outcome of infection confirmed by PCR, RAT, or seroconversion, which was limited to primary series BNT162b2 vaccination, we found similar trends. VE was 32% (95%CI: 0; 53) overall, 15% (95%CI: -31; –44) for those without previous infection, and 69% (95%CI: 26; 87) for those with previous infection (Table S3). Compared to unvaccinated participants who had not been previously infected, aVE was 15% (95%CI: -31; 44) for primary series vaccination without previous infection, and 96% (95%CI: 92–98) for primary series vaccination among participants with prior infection. Unvaccinated participants who had been previous infected had 90% (95%CI: 87; 93) protection from re-infection (Table S4).
In our evaluation of VE against symptomatic PCR- and RAT-confirmed SARS-CoV-2 infection stratified by time since vaccination, for the overall analysis, (Table 5 and Figure 5), VE was 60% (95%CI: 39; –74) for participants 14–89 days after their second vaccine dose, 48% (95%CI: 18; 66) for participants who were 90-179 days after their second vaccine dose, and 14% (95%CI: -134; 68) for those ≥180 days. When we restricted the time-since-vaccination analysis to vaccine product and the Delta-predominant period, the trends were similar (Table 5. Figure 5).
Table S5 presents the identified confounders for each model.
Discussion
We found that primary series COVID-19 vaccination was nearly 60% effective in preventing symptomatic SARS-CoV-2 illness among Georgian HCWs, most of whom had been previously infected with SARS-CoV-2, during a period of mostly Delta variant circulation. Both primary series BNT162b2 vaccination and primary series BBIBP-CorV vaccination conferred similarly high VE against symptomatic infection. Our findings support the current recommendations of Georgia that HCWs, and all adults over 18 years old, should receive primary series COVID-19 vaccination. The results from this study, which to our knowledge is the first study to describe COVID-19 VE in Georgia, could be used to promote increased COVID-19 vaccination in the country, which has one of the lowest COVID-19 vaccination rates in the WHO European region; as of the week of 4 June 2023 only 57% of Georgian HCWs had received primary series COVID-19 vaccination, and only 18% had received a booster dose. As of the same date, only 32% of the general population in Georgia had received primary series COVID-19 vaccination, and only 6% had received a booster dose.8
Our findings of primary series BNT162b2 VE against symptomatic SARS-CoV-2 infection are similar to other previously published studies that evaluated VE against COVID-19 during periods of Delta circulation. A living active VE literature review and associated systematic review6 [17]described point estimates for studies that evaluated primary series BNT162b2 VE against symptomatic disease during Delta ranging from 80-95% in the 14 days to <3 months following completion of the primary series; VE dropped to 45-80% after 3-6 months.7 Studies from other regions of the world have demonstrated a consistently relatively high VE (70%) of primary series BNT162b2 against severe disease, which has increased following booster doses.7
Although well over 1.5 billion doses of BBIBP-CorV have been used globally,[18] very few post-marketing studies have evaluated its effectiveness.7 Our study is one of few studies globally to evaluate VE of primary series BBIBP-CorV against symptomatic infection during the Delta period.[7] Our finding of 40% VE was in the range of primary series BBIBP-CorV VE against symptomatic infection during Delta described in two studies from China, which found aVE of 50% (95%CI: 4; –74)[19] and 75 (95%CI: 6; –94)[20], and one study from Egypt, that found VE of 67% (95%CI: 43; 80).[21] Studies of BBIBP-CoRV against more severe outcomes have shown mixed results, but have consistently shown the added benefit of booster doses, mostly against Delta but also against Omicron; a study of primary series BBIBP-CorV VE against hospitalization among people aged 18-64 years old in Hungary during Delta found a VE of 54% (44; 62) in the 14-120 days following the second dose that decreased over time, but increased to 77-95% following homologous or heterologous booster;[22] for 65-100 year-olds, the same study found slightly lower VE against hospitalization with similar trends following booster doses. A study during a period of primarily Delta circulation in Iran found that primary series BBIBP-CorV VE peaked at 85% (95%CI: 77; 91%) against hospitalization ≥ 151 days after receipt of the second dose and 56% (95% CI 33; 71%) against death 91-120 days after receipt of the second dose.23 A study from Thailand found BBIBP-CorV primary series VE against pneumonia requiring invasive ventilation during Omicron of 66% (95%CI: 39; 81%) that had a non-statistically significant increase to 81% (95%CI: 36; 95%) following a booster dose.[24]
In our study, nearly two-thirds of participants (64%) had been previously infected with SARS-CoV-2 at the time of their enrolment into the study. Nevertheless, we found clear benefit to COVID-19 vaccination; among participants with prior infection, primary series VE with any vaccine was 58%. The benefits of hybrid immunity – immunity conferred by the combination of vaccination and infection – have been widely described globally and within the WHO European region.[25–27] The added benefit of vaccination after infection is becoming an increasingly important public message as more of the world’s population has experienced at least one SARS-CoV-2 infection.[28]
Our study had a number of strengths. By using PCR-confirmed infection and serology to define prior infection, and by using these two diagnostic tools and RAT to estimate VE against all infections, we were able to more comprehensively identify infections among participants in our study. In addition, by collecting quarterly serology samples, we were able to identify asymptomatic infections and symptomatic infections that may have been missed by PCR on one-time swab collection. Very few participants [3/1592 (0.2%)] withdrew from the study during the follow-up period. In addition, 85% of participants who reported a symptomatic illness on their weekly questionnaire had a specimen collected for PCR testing.
Our study also has limitations. First, while we evaluated COVID-19 VE against symptomatic and asymptomatic infections, endpoints that are particularly relevant for HCWs, who need to be healthy in order to provide clinical care and infection-free so that they do not pass on the virus to their patients, our study was not powered to estimate VE against severe outcomes such as hospitalization and death. In addition, our study evaluated primary series VE during a period of Delta circulation, and could not evaluate VE of booster doses; both will be evaluated in future analyses of this ongoing cohort study. Our study may suffer from selection bias; enrolment in the study was voluntary, HCWs in our study may not fully represent HCWs in Georgia. However, we did enroll over 40% of eligible HCWs in the six hospitals. Additionally, while serology was a strength of our study in identifying previous infections and new infections (in those participants who were not vaccinated with inactivated virus vaccines), our anti-nucleocapsid antibody likely did not capture all previous infections, due to a combination of antibody waning, imperfect sensitivity of the assay, and potentially variable production of anti-nucleocapsid antibodies in vaccinated individuals. [29] While the Georgian government encouraged routine testing of all HCWs during the study period, not all HCWs in our study were tested routinely with the same frequency, which may have introduced bias. In our study the unvaccinated group at the end of the study period was slightly younger and included more physicians; however, in order to address these differences, we controlled for age and occupation in our final adjusted models.
Conclusions
In conclusion, we found that a primary series COVID-19 vaccination, which included mainly BNT162b2 vaccine and, to a lesser extent, BBIBP-CorV, was effective in preventing symptomatic infection in hospital-based HCWs in Georgia. Our findings support current vaccine policy and underscore the need to promote vaccine uptake in Georgia both in HCWs and the general population, where uptake has lagged in comparison to most other countries in the European region of WHO. Our findings also add to the growing literature on the added benefit of COVID-19 vaccination in individuals who have been previously infected with SARS-CoV-2.
Author Contributions
Conceptualization, Mark Katz, Giorgi Chakhunashvili, Nazibrola Chitadze, C. McKnight, Tamila Zardiashvili, Richard Pebody, Esther Kissling and Lia Sanodze; Data curation, Madelyn Castro, Giorgi Chakhunashvili, Nazibrola Chitadze, Caleb Ward, Héloïse Lucaccioni, Iris Finci, Esther Kissling and Lia Sanodze; Formal analysis, Madelyn Castro and Esther Kissling; Funding acquisition, Mark Katz, Tamila Zardiashvili, Richard Pebody and Lia Sanodze; Investigation, Mark Katz, Giorgi Chakhunashvili, Nazibrola Chitadze, Caleb Ward, C. McKnight, Héloïse Lucaccioni, Iris Finci, Tamila Zardiashvili and Lia Sanodze; Methodology, Mark Katz, Madelyn Castro, Giorgi Chakhunashvili, C. McKnight, Héloïse Lucaccioni, Iris Finci, Richard Pebody, Esther Kissling and Lia Sanodze; Project administration, C. McKnight, Héloïse Lucaccioni, Iris Finci and Lia Sanodze; Resources, Lia Sanodze; Supervision, Mark Katz, Iris Finci and Lia Sanodze; Validation, Giorgi Chakhunashvili, Caleb Ward and Esther Kissling; Visualization, Iris Finci and Lia Sanodze; Writing – original draft, Mark Katz; Writing – review & editing, Mark Katz, Madelyn Castro, Giorgi Chakhunashvili, Nazibrola Chitadze, Caleb Ward, C. McKnight, Héloïse Lucaccioni, Iris Finci, Tamila Zardiashvili, Richard Pebody, Esther Kissling and Lia Sanodze.
Funding
This study was supported by funding from the World Health Organization/European Regional Office, the US Centers for Disease Control and Prevention (Cooperative Agreement No.: NU2GGH002093), and the Public Health Institute
Acknowledgements
We are grateful to the study team at the Georgia National Centers for Disease Control and at all the participating study hospitals. In addition we would like to thank the following colleagues: Pernille Jorgensen and Diogo Simao Lemos (WHO Regional Office for Europe), Irina Begiashvilli (WHO Country Office in Georgia), Lindsey Duca (US CDC), Marta Valenciano and Alain Moren (Epiconcept). This study has been conducted within the framework of the WHO Strategic Preparedness and Response plan and WHO/European Regional Office Response for COVID-19.
Conflict of Interest: None of the authors report any conflicts of interest
Disclaimer: The authors affiliated with the World Health Organization (WHO) are alone responsible for the views expressed in this publication, and they do not necessarily represent the decisions or the policies of the WHO.
References
- Bandyopadhyay S, Baticulon RE, Kadhum M, et al. Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review. BMJ Glob Health. 2020;5(12). [CrossRef]
- Hamid H, Abid Z, Amir A, Rehman TU, Akram W, Mehboob T. Current burden on healthcare systems in low- and middle-income countries: recommendations for emergency care of COVID-19. Drugs & Therapy Perspectives. 2020;36(10):466. [CrossRef]
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed June 30, 2022. https://covid19.who.int/.
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-1302. [CrossRef]
- Meslé MMI, Brown J, Mook P, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Eurosurveillance. 2021;26(47):2101021. [CrossRef]
- WDI - The World by Income and Region. Accessed October 3, 2023. https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html.
- Effectiveness Studies | ViewHub. Accessed September 12, 2022. https://view-hub.org/covid-19/effectiveness-studies.
- WHO/Europe Covid-19 vaccine programme monitor. Accessed October 17, 2022. https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/.
- WHO Europe. WHO/Europe COVID-19 Vaccine Programme Monitor. Accessed July 11, 2022. https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/.
- Lucaccioni H, Chakhunashvili G, McKnight CJ, et al. Sociodemographic and Occupational Factors Associated with Low Early Uptake of COVID-19 Vaccine in Hospital-Based Healthcare Workers, Georgia, March–July 2021. Vaccines (Basel). 2022;10(8):1197. [CrossRef]
- World Health Organization. Regional Office for Europe. Cohort Study to Measure COVID-19 Vaccine Effectiveness among Healthcare Workers in the WHO European Region: Guidance Document.; 2021.
- World Health Organization. Coronavirus disease (COVID-19) technical guidance: The Unity Studies: Early Investigation Protocols. Accessed November 8, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2). [CrossRef]
- Riester E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. J Virol Methods. 2021;297:114271. [CrossRef]
- Khare S, Gurry C, Freitas L, et al. GISAID’s Role in Pandemic Response. China CDC Wkly. 2021;3(49):1049-1051. [CrossRef]
- Wajnberg A, Mansour M, Leven E, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe. 2020;1(7):e283-e289. [CrossRef]
- Higdon MM, Wahl B, Jones CB, et al. A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infect Dis. 2022;9(6). [CrossRef]
- Mallapaty S. China’s COVID vaccines have been crucial - now immunity is waning. Nature. 2021;598(7881):398-399. [CrossRef]
- Wu D, Zhang Y, Tang L, et al. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021. China CDC Weekly, 2022, Vol 4, Issue 4, Pages: 57-65. 2022;4(4):57-65. [CrossRef]
- Ma C, Sun W, Tang T, et al. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. Vaccine. 2022;40(20):2869-2874. [CrossRef]
- Fahmy Esmail O, Drug Authority E, Samar Kabeel E. Effectiveness and safety of inactivated SARS-CoV2 vaccine (BBIBP-CorV) among healthcare workers: A seven-month follow-up study at fifteen hospitals. Published online March 11, 2022. [CrossRef]
- Vokó Z, Kiss Z, Surján G, et al. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). Front Immunol. 2022;13:3609. [CrossRef]
- Heidarzadeh A, Amini Moridani M, Khoshmanesh S, Kazemi S, Hajiaghabozorgi M, Karami M. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. International Journal of Infectious Diseases. 2023;128:212-222. [CrossRef]
- Nittayasoot N, Suphanchaimat R, Thammawijaya P, et al. Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case–Control Study. Vaccines 2022, Vol 10, Page 2123. 2022;10(12):2123. [CrossRef]
- The Lancet Infectious Diseases. Why hybrid immunity is so triggering. Lancet Infect Dis. 2022;22(12):1649. [CrossRef]
- Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. New England Journal of Medicine. 2022;386(13):1207-1220. [CrossRef]
- Rubin-Smith J, Rojas Castro MY, Preza I, et al. Primary Series COVID-19 Vaccine Effectiveness Among Health Care Workers in Albania, February–December 2021. SSRN Electronic Journal. Published online 2022. [CrossRef]
- Interim statement on hybrid immunity and increasing population seroprevalence rates. Accessed January 2, 2023. https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates.
- Dhakal S, Yu T, Yin A, et al. Reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection post-vaccination for mild COVID-19 patients. Open Forum Infect Dis. Published online December 15, 2022. [CrossRef]
Figure 1.
Flowchart illustrating the enrolment of healthcare workers in COVID-19 vaccine effectiveness study, Georgia, 2021.
Figure 1.
Flowchart illustrating the enrolment of healthcare workers in COVID-19 vaccine effectiveness study, Georgia, 2021.
Figure 2.
COVID-19 vaccine coverage in the study population, by epidemiological week, Georgia, 2021.
Figure 2.
COVID-19 vaccine coverage in the study population, by epidemiological week, Georgia, 2021.
Figure 3.
Number of symptomatic COVID-19 cases by vaccination status in the study population and national COVID-19 incidence in Georgia, by epidemiologic week, 2021.
Figure 3.
Number of symptomatic COVID-19 cases by vaccination status in the study population and national COVID-19 incidence in Georgia, by epidemiologic week, 2021.
Figure 4.
COVID-19 vaccine effectiveness against symptomatic infection and medically attended cohort for total study cohort, and stratified by previous infection status, for overall study period, and for Delta-predominant period, Georgia, 2021.
Figure 4.
COVID-19 vaccine effectiveness against symptomatic infection and medically attended cohort for total study cohort, and stratified by previous infection status, for overall study period, and for Delta-predominant period, Georgia, 2021.
Figure 5.
COVID-19 primary series vaccine effectiveness by days since vaccination against symptomatic infection for overall cohort during entire study period, overall cohort during the Delta-predominant period, and for BNT162b2 during the Delta-predominant period, Georgia, 2021.
Figure 5.
COVID-19 primary series vaccine effectiveness by days since vaccination against symptomatic infection for overall cohort during entire study period, overall cohort during the Delta-predominant period, and for BNT162b2 during the Delta-predominant period, Georgia, 2021.
Table 1.
Demographic, Occupational and Health Characteristics, Prior Infection Status of Participants in COVID-19 Vaccine Effectiveness study, by vaccination status at enrolment, Georgia, 2021.
Table 1.
Demographic, Occupational and Health Characteristics, Prior Infection Status of Participants in COVID-19 Vaccine Effectiveness study, by vaccination status at enrolment, Georgia, 2021.
| Characteristic/Category | All Participants, n=1561 | Unvaccinated, n=1300 | Partially vaccinated (1 dose), n=224 | Vaccinated with primary series (2 doses), n=37 |
|---|---|---|---|---|
| Age, n=1561 | ||||
| Median (IQR) | 40 (30-53) | 40 (28.8-52) | 47 (35-56.2) | 40 (31-52) |
| Age group, n=1561 | ||||
| <20, n (%) | 16 (1) | 15 (1) | 1 (<1) | 0 (0) |
| 20-29, n (%) | 373 (24) | 335 (26) | 31 (14) | 7 (19) |
| 30-39, n (%) | 343 (22) | 291 (22) | 42 (19) | 10 (27) |
| 40-49, n (%) | 330 (21) | 270 (21) | 51 (23) | 9 (24) |
| 50-59, n (%) | 314 (20) | 248 (19) | 60 (27) | 6 (16) |
| 60+, n (%) | 185 (12) | 141 (11) | 39 (17) | 5 (14) |
| Sex, n=1561 | ||||
| female, n (%) | 1318 (84) | 1105 (85) | 189 (84) | 24 (65) |
| male, n (%) | 243 (16) | 195 (15) | 35 (16) | 13 (35) |
| Hospital, n=1561 | ||||
| Acad. K Central University Hosp., n (%) | 300 (19) | 240 (18) | 49 (22) | 11 (30) |
| Batumi Republican Hospital, n (%) | 276 (18) | 216 (17) | 52 (23) | 8 (22) |
| Bochorishvili Clinic, n (%) | 194 (12) | 178 (14) | 14 (6) | 2 (5) |
| Bokeria Tbilisi Referral Hospital, n (%) | 309 (20) | 266 (20) | 37 (17) | 6 (16) |
| Caucasus Medical Centre, n (%) | 299 (19) | 251 (19) | 40 (18) | 8 (22) |
| Infectious Disease Hospital, n (%) | 183 (12) | 149 (11) | 32 (14) | 2 (5) |
| Occupation/Role in hospital, n=1561 | ||||
| Nurse or Midwife, n (%) | 604 (39) | 537 (41) | 58 (26) | 9 (24) |
| Medical Doctor, n (%) | 306 (20) | 181 (14) | 108 (48) | 17 (46) |
| Other, n (%) | 651 (42) | 582 (45) | 58 (26) | 11 (30) |
| Household size, n=1561 | ||||
| 1-3, n (%) | 703 (45) | 579 (45) | 107 (48) | 17 (46) |
| 4-5, n (%) | 622 (40) | 526 (40) | 83 (37) | 13 (35) |
| 6+, n (%) | 236 (15) | 195 (15) | 34 (15) | 7 (19) |
| Any chronic condition, n=1561 | ||||
| No, n (%) | 1171 (75) | 988 (76) | 155 (69) | 28 (76) |
| Yes, n (%) | 390 (25) | 312 (24) | 69 (31) | 9 (24) |
| Number of chronic conditions, n=1561 | ||||
| 0, n (%) | 1171 (75) | 988 (76) | 155 (69) | 28 (76) |
| 1, n (%) | 307 (20) | 252 (19) | 48 (21) | 7 (19) |
| ≥2, n (%) | 83 (5) | 60 (5) | 21 (9) | 2 (5) |
| Body mass index, n=1561 | ||||
| Underweight or normal, n (%) | 721 (46) | 607 (47) | 101 (45) | 13 (35) |
| Overweight, n (%) | 481 (31) | 394 (30) | 74 (33) | 13 (35) |
| Obese, n (%) | 359 (23) | 299 (23) | 49 (22) | 11 (30) |
| Smoking, n=1560 | ||||
| Currently smokes, n (%) | 388 (25) | 323 (25) | 48 (21) | 17 (46) |
| Never smokes, n (%) | 1030 (66) | 865 (67) | 148 (66) | 17 (46) |
| Previously smokes, n (%) | 142 (9) | 111 (9) | 28 (12) | 3 (8) |
| Self-assessed health status, n=1561 | ||||
| Excellent, n (%) | 127 (8) | 104 (8) | 17 (8) | 6 (16) |
| Very good, n (%) | 252 (16) | 206 (16) | 37 (17) | 9 (24) |
| Good, n (%) | 521 (33) | 438 (34) | 68 (30) | 15 (41) |
| Fair, n (%) | 641 (41) | 533 (41) | 101 (45) | 7 (19) |
| Poor, n (%) | 20 (1) | 19 (1) | 1 (<1) | 0 (0) |
| Hands on care, n=1561 | ||||
| No, n (%) | 745 (48) | 639 (49) | 91 (41) | 15 (41) |
| Yes, n (%) | 816 (52) | 661 (51) | 133 (59) | 22 (59) |
| Received influenza vaccine during 2020-2021 influenza season, n=1561 | ||||
| No, n (%) | 1068 (68) | 944 (73) | 105 (47) | 19 (51) |
| Yes, n (%) | 492 (32) | 355 (27) | 119 (53) | 18 (49) |
| Face-to-face patient contact, n=1561 | ||||
| No, n (%) | 336 (22) | 292(22) | 37 (17) | 7 (19) |
| Yes, n (%) | 1125 (78) | 1008 (78) | 187 (81) | 30 (81) |
| Previous SARS-CoV-2 infection (before enrollment) confirmed by PCR or RAT, n=1561 | ||||
| 0, n (%) | 814 (52) | 645 (50) | 136 (61) | 33 (89) |
| 1, n (%) | 747 (48) | 655 (50) | 88 (39) | 4 (11) |
| Previous SARS-CoV-2 infection (before enrollment) confirmed by any test: PCR, RAT or serology, n=1561 | ||||
| 0, n (%) | 558 (36) | 437 (34) | 120 (54) | 1 (3) |
| 1, n (%) | 1003 (64) | 863 (66) | 104 (46) | 36 (97) |
| Seropositive at enrolment (AntiS+ or AntiN+), n=1555 | ||||
| 0, n (%) | 569 (37) | 446 (34) | 122 (55) | 1 (3) |
| 1, n (%) | 986 (63) | 850 (66) | 100 (45) | 36 (97) |
| Anti-S+, n=1558 | ||||
| 0, n (%) | 589 (38) | 460 (35) | 124 (56) | 5 (14) |
| 1, n (%) | 969 (62) | 838 (65) | 99 (44) | 32 (86) |
| Anti-N+, n=1552 | ||||
| 0, n (%) | 639 (41) | 502 (39) | 130 (59) | 7 (19) |
| 1, n (%) | 913 (59) | 791 (61) | 92 (41) | 30 (81) |
| Delay between first dose and start of person-time contribution, in days (n=261) | ||||
| Median (IQR) | 2 (1-4) | _ | 2 (1-3) | 30 (29-31) |
| Delay between second dose and start of person-time contribution, in days (n=37) | ||||
| )Median (IQR) | 7 (3-9) | _ | _ | 7 (3-9) |
| COVID-19 Vaccine product received prior to start of person-time contribution, n= 1561 | ||||
| Unvaccinated, n (%) | 1300 (83) | 1300 (100) | 0 (0) | 0 (0) |
| ChAdOx1-S - 2 doses, n (%) | 3 (<1) | 0 (0) | 0 (0) | 3 (8) |
| BNT162b2 - 1 dose, n (%) | 145 (9) | 0 (0) | 145 (65) | 0 (0) |
| BNT162b2 - 2 dose, n (%) | 26 (2) | 0 (0) | 0 (0) | 26 (70) |
| BBIBP-CorV - 1 dose, n (%) | 33 (2) | 0 (0) | 33 (15) | 0 (0) |
| BBIBP-CorV - 2 dose, n (%) | 4 (<1) | 0 (0) | 0 (0) | 4 (11) |
| CoronaVac - 1 dose, n (%) | 28 (2) | 0 (0) | 28 (12) | 0 (0) |
| CoronaVac - 2 doses, n (%) | 4 (<1) | 0 (0) | 0 (0) | 4 (11) |
Table 2.
Vaccine effectiveness against symptomatic PCR and rapid antigen test confirmed SARS-CoV-2 infection for full cohort, and stratified by previous infection, vaccine brand and variant of interest.
Table 2.
Vaccine effectiveness against symptomatic PCR and rapid antigen test confirmed SARS-CoV-2 infection for full cohort, and stratified by previous infection, vaccine brand and variant of interest.
| N participants | Total person-time (days) | PCR-confirmed symptomatic SARS-CoV-2 infection | RAT- confirmed symptomatic SARS-CoV-2 infection | All symptomatic SARS-CoV-2 infections | Unadjusted HR | (95% CI) | Unadjusted VE | (95%CI) | Adjusted VE | (95%CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall study period | Two doses - any vaccine | |||||||||||
| Total cohort | 1561 | |||||||||||
| Unvaccinated | 1300 | 112050 | 90 | 34 | 124 | |||||||
| ≥14d from 2nd dose | 1054 | 105080 | 52 | 15 | 67 | 0.56 | (0.40; 0.80) | 44 | (20; 60) | 58 | (41; 70) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 63 | 25 | 88 | |||||||
| ≥14d from 2nd dose | 357 | 37683 | 40 | 14 | 54 | 0.48 | (0.32; 0.70) | 52 | (30; 68) | 56 | (35; 70) | |
| With Prior Infection | ||||||||||||
| Unvaccinated | 863 | 75941 | 27 | 9 | 36 | |||||||
| ≥14d from 2nd dose | 697 | 67397 | 12 | 1 | 13 | 0.41 | (0.20; 0.84) | 59 | (16; 80) | 58 | (11; 80) | |
| Two doses - BNT162b2 vaccine | ||||||||||||
| Total cohort | 1470 | |||||||||||
| Unvaccinated | 1300 | 112050 | 90 | 34 | 124 | |||||||
| ≥14d from 2nd dose | 732 | 72695 | 25 | 6 | 31 | 0.40 | (0.26; 0.63) | 60 | (37; 74) | 68 | (51; 79) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 63 | 25 | 88 | |||||||
| ≥14d from 2nd dose | 239 | 25763 | 22 | 6 | 28 | 0.37 | (0.24; 0.60) | 63 | (40; 76) | 63 | (43; 77) | |
| Two doses - BBIBP-CorV vaccine | ||||||||||||
| Total cohort | 1337 | |||||||||||
| Unvaccinated | 1300 | 112050 | 90 | 34 | 124 | |||||||
| ≥14d from 2nd dose | 227 | 21136 | 18 | 6 | 24 | 0.87 | (0.52; 1.45) | 13 | (-45; 48) | 40 | (1; 64) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 63 | 25 | 88 | |||||||
| ≥14d from 2nd dose | 91 | 8977 | 15 | 5 | 20 | 0.74 | (0.41; 1.33) | 26 | (-33; 59) | 31 | (-26; 62) | |
| Delta period | Two doses - any vaccine | |||||||||||
| Total cohort | 1556 | |||||||||||
| Unvaccinated | 1162 | 72917 | 67 | 25 | 92 | |||||||
| ≥14d from 2nd dose | 1068 | 96751 | 49 | 15 | 64 | 0.60 | (0.41; 0.86) | 40 | (14; 59) | 52 | (30; 66) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 378 | 21896 | 45 | 19 | 64 | |||||||
| ≥14d from 2nd dose | 339 | 30932 | 36 | 12 | 48 | 0.53 | (0.35; 0.80) | 47 | (20; 65) | 52 | (26; 69) | |
| With Prior Infection | ||||||||||||
| Unvaccinated | 784 | 51021 | 22 | 6 | 28 | |||||||
| ≥14d from 2nd dose | 729 | 65819 | 13 | 3 | 16 | 0.49 | (0.25; 0.98) | 51 | (2; 75) | 47 | (-10; 74) | |
| Two doses - BNT162b2 vaccine | ||||||||||||
| Total cohort | 1371 | |||||||||||
| Unvaccinated | 1162 | 72917 | 67 | 25 | 92 | |||||||
| ≥14d from 2nd dose | 733 | 64109 | 23 | 6 | 29 | 0.46 | (0.28; 0.73) | 54 | (27; 72) | 61 | (38; 75) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 378 | 21896 | 45 | 19 | 64 | |||||||
| ≥14d from 2nd dose | 222 | 19615 | 19 | 5 | 24 | 0.46 | (0.28; 0.77) | 54 | (23; 72) | 55 | (26; 73) | |
| Two doses - BBIBP-CorV vaccine | ||||||||||||
| Total cohort | 1250 | |||||||||||
| Unvaccinated | 1161 | 72906 | 67 | 25 | 92 | |||||||
| ≥14d from 2nd dose | 227 | 20221 | 18 | 6 | 24 | 0.88 | (0.52; 1.5) | 12 | (-50; 48) | 37 | (-9; 63) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 378 | 21896 | 45 | 19 | 64 | |||||||
| ≥14d from 2nd dose | 91 | 8474 | 15 | 5 | 20 | 0.72 | (0.39; 1.31) | 28 | (-31; 61) | 34 | (-23; 64) | |
* due to the small number of events, brand-specific VE in participants with previous infection could not be estimated.
Table 3.
Vaccine effectiveness against medically attended COVID-19 and COVID-19 hospitalization, for full cohort, and stratified by previous infection, vaccine product, for overall study period and for Delta-predominant period, Georgia, 2021.
Table 3.
Vaccine effectiveness against medically attended COVID-19 and COVID-19 hospitalization, for full cohort, and stratified by previous infection, vaccine product, for overall study period and for Delta-predominant period, Georgia, 2021.
| N participants | Total person-time (days) | PCR-confirmed symptomatic SARS-CoV-2 infection | RAT-confirmed symptomatic SARS-CoV-2 infection | All symptomatic SARS-CoV-2 infections | Unadjusted HR | (95% CI) | Unadjusted VE | (95%CI) | Adjusted VE | (95%CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall period | Medically attended SARS-CoV-2 infection | |||||||||||
| Two doses - any vaccine | ||||||||||||
| Total cohort | 1561 | |||||||||||
| Unvaccinated | 1300 | 112050 | 64 | 22 | 86 | |||||||
| ≥14d from 2nd dose | 1054 | 105080 | 37 | 9 | 46 | 0.64 | (0.43; 0.95) | 36 | (5; 57) | 52 | (28; 67) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 47 | 15 | 62 | |||||||
| ≥14d from 2nd dose | 357 | 37683 | 30 | 8 | 38 | 0.55 | (0.35; 0.85) | 45 | (15; 65) | 51 | (21; 70) | |
| With Prior Infection | ||||||||||||
| Unvaccinated | 863 | 75941 | 17 | 7 | 24 | |||||||
| ≥14d from 2nd dose | 697 | 67397 | 7 | 1 | 8 | 0.42 | (0.18; 0.98) | 58 | (2; 82) | 56 | (-2; 81) | |
| Two doses - BNT162b2 | ||||||||||||
| Total cohort | 1470 | |||||||||||
| Unvaccinated | 1300 | 112050 | 64 | 22 | 86 | |||||||
| ≥14d from 2nd dose | 732 | 72695 | 18 | 5 | 23 | 0.49 | (0.30; 0.81) | 51 | (19; 70) | 63 | (39; 78) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 47 | 15 | 62 | |||||||
| ≥14d from 2nd dose | 239 | 25763 | 16 | 5 | 21 | 0.44 | (0.26; 0.75) | 56 | (25; 74) | 54 | (24; 72) | |
| Delta period | Two doses - any vaccine | |||||||||||
| Total cohort | 1556 | |||||||||||
| Unvaccinated | 1162 | 72917 | 45 | 13 | 58 | |||||||
| ≥14d from 2nd dose | 1068 | 96751 | 35 | 9 | 44 | 0.69 | (0.45; 1.08) | 31 | (-8; 55) | 41 | (10; 61) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 378 | 21896 | 31 | 9 | 40 | |||||||
| ≥14d from 2nd dose | 339 | 30932 | 28 | 7 | 35 | 0.68 | (0.42; 1.11) | 32 | (-11; 58) | 35 | (-6; 60) | |
| With Prior Infection | ||||||||||||
| Unvaccinated | 784 | 51021 | 14 | 4 | 18 | |||||||
| ≥14d from 2nd dose | 729 | 65819 | 7 | 2 | 9 | 0.44 | (0.19; 1.02) | 56 | (-2; 81) | 53 | (-13; 80) | |
| Overall period | Hospitalization due to SARS-CoV-2 infection | |||||||||||
| Two doses - any vaccine | ||||||||||||
| Total cohort | 1561 | |||||||||||
| Unvaccinated | 1300 | 112050 | 25 | 8 | 33 | |||||||
| ≥14d from 2nd dose | 1054 | 105080 | 9 | 2 | 11 | 0.46 | (0.22; 0.96) | 54 | (4; 78) | 69 | (36; 85) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 437 | 36109 | 21 | 6 | 27 | |||||||
| ≥14d from 2nd dose | 357 | 37683 | 8 | 2 | 10 | 0.37 | (0.18; 0.78) | 63 | (22; 82) | 66 | (29; 84) | |
| Delta period | Two doses - any vaccine | |||||||||||
| Total cohort | 1556 | |||||||||||
| Unvaccinated | 1162 | 72917 | 13 | 3 | 16 | |||||||
| ≥14d from 2nd dose | 1068 | 96751 | 8 | 2 | 10 | 0.5 | (0.21; 1.17) | 50 | (-17; 79) | 61 | (13; 81) | |
| Without Prior Infection | ||||||||||||
| Unvaccinated | 378 | 21896 | 10 | 2 | 12 | |||||||
| ≥14d from 2nd dose | 339 | 30932 | 7 | 2 | 9 | 0.46 | (0.19; 1.11) | 54 | (-11; 81) | 53 | (-13; 81) | |
* due to small number of events, brand specific VE in participants with previous infection could not be estimated **Because of the low number of events, BNT162b2 aVE against hospitalization could not be calculated, and BBIBP-CorV aVe against medically attended COVID-19 and hospitalization could not be calculated.
Table 4.
Combined effect of previous infection and primary series vaccination in protecting against symptomatic PCR and/or RAT-confirmed SARS-CoV-2 infection, overall, by vaccine product, and for Delta-predominant period only, Georgia, 2021.
Table 4.
Combined effect of previous infection and primary series vaccination in protecting against symptomatic PCR and/or RAT-confirmed SARS-CoV-2 infection, overall, by vaccine product, and for Delta-predominant period only, Georgia, 2021.
| N participants | Total person-time (days) | PCR-confirmed symptomatic SARS-CoV-2 infection | RAT-confirmed symptomatic SARS-CoV-2 infection | All symptomatic SARS-CoV-2 infections | Unadjusted HR | (95% CI) | Unadjusted VE | (95%CI) | Adjusted VE | (95%CI) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall period | Two doses (all vaccines) | 1561 | ||||||||||
| Unvaccinated without previous infection [ref] | 437 | 36109 | 63 | 25 | 88 | |||||||
| Unvaccinated with previous infection | 863 | 75941 | 27 | 9 | 36 | 0.17 | (0.11; 0.25) | 83 | (75; 89) | 85 | (77; 90) | |
| ≥14d from 2nd dose without previous infection | 357 | 37683 | 40 | 14 | 54 | 0.48 | (0.32; 0.70) | 52 | (30; 68) | 56 | (35; 70) | |
| ≥14d from 2nd dose with previous infection | 697 | 67397 | 12 | 1 | 13 | 0.06 | (0.03; 0.13) | 94 | (87; 97) | 95 | (90; 98) | |
| Two doses (BNT162b2) | 1470 | |||||||||||
| Unvaccinated without previous infection [ref] | 437 | 36109 | 63 | 25 | 88 | |||||||
| Unvaccinated with previous infection | 863 | 75941 | 27 | 9 | 36 | 0.17 | (0.11; 0.25) | 83 | (75; 89) | 85 | (77; 90) | |
| ≥14d from 2nd dose without previous infection | 239 | 25763 | 22 | 6 | 28 | 0.37 | (0.24; 0.60) | 63 | (40; 76) | 64 | (43; 77) | |
| Two doses (BBIBP-CorV) | 1337 | |||||||||||
| Unvaccinated without previous infection [ref] | 437 | 36109 | 63 | 25 | 88 | |||||||
| Unvaccinated with previous infection | 863 | 75941 | 27 | 9 | 36 | 0.17 | (0.11; 0.25) | 83 | (75; 89) | 85 | (77; 90) | |
| ≥14d from 2nd dose without previous infection | 91 | 8977 | 15 | 5 | 20 | 0.74 | (0.41; 1.33) | 26 | (-33; 59) | 31 | (-26; 62) | |
| Delta period | Two doses (all vaccines) | 1556 | ||||||||||
| Unvaccinated without previous infection [ref] | 378 | 21896 | 45 | 19 | 64 | |||||||
| Unvaccinated with previous infection | 784 | 51021 | 22 | 6 | 28 | 0.17 | (0.11; 0.27) | 83 | (73; 89) | 86 | (77; 91) | |
| ≥14d from 2nd dose without previous infection | 339 | 30932 | 36 | 12 | 48 | 0.53 | (0.35; 0.80) | 47 | (20; 65) | 52 | (26; 69) | |
| ≥14d from 2nd dose with previous infection | 729 | 65819 | 13 | 3 | 16 | 0.08 | (0.04; 0.16) | 92 | (84; 96) | 93 | (86; 96) | |
| Two doses (BNT162b2)/Previous infection status | 1371 | |||||||||||
| Unvaccinated without previous infection [ref] | 378 | 21896 | 45 | 19 | 64 | |||||||
| Unvaccinated with previous infection | 784 | 51021 | 22 | 6 | 28 | 0.17 | (0.11; 0.27) | 83 | (73; 89) | 86 | (77; 91) | |
| ≥14d from 2nd dose without previous infection | 222 | 19615 | 19 | 5 | 24 | 0.46 | (0.28; 0.77) | 54 | (23; 72) | 55 | (26; 73) | |
| Two doses (BBIBP-CorV) | 1250 | |||||||||||
| Unvaccinated without previous infection [ref] | 378 | 21896 | 45 | 19 | 64 | |||||||
| Unvaccinated with previous infection | 783 | 51010 | 22 | 6 | 28 | 0.17 | (0.11; 0.27) | 83 | (73; 89) | 86 | (77; 91) | |
| ≥14d from 2nd dose without previous infection | 91 | 8474 | 15 | 5 | 20 | 0.72 | (0.39; 1.31) | 28 | (-31; 61) | 34 | (-23; 64) |
Table 5.
Effect of time since vaccination on COVID-19 primary vaccine series effectiveness against symptomatic PCR- and RAT-confirmed infection, for full cohort, by vaccine product, and for Delta-predominant period, Georgia, 2021.
Table 5.
Effect of time since vaccination on COVID-19 primary vaccine series effectiveness against symptomatic PCR- and RAT-confirmed infection, for full cohort, by vaccine product, and for Delta-predominant period, Georgia, 2021.
| N participants | Total person-time (days) | PCR-confirmed symptomatic SARS-CoV-2 infection | RAT-confirmed symptomatic SARS-CoV-2 infection | All symptomatic SARS-CoV-2 infections | Unadjusted HR | (95% CI) | Unadjusted VE | (95%CI) | Adjusted VE | (95%CI) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall period | Time since two doses (all vaccines) | 1561 | |||||||||||
| Unvaccinated [ref] | 1300 | 112050 | 90 | 34 | 124 | ||||||||
| 14d - 89d from 2nd dose | 1054 | 71373 | 28 | 7 | 35 | 0.47 | (0.30; 0.72) | 53 | (28; 70) | 60 | (39; 74) | ||
| 90d-179d from 2nd dose | 697 | 29150 | 19 | 7 | 26 | 0.73 | (0.46; 1.16) | 27 | (-16; 54) | 48 | (18; 66) | ||
| ≥180d from 2nd dose | 186 | 4557 | 5 | 1 | 6 | 0.92 | (0.36; 2.38) | 8 | (-138; 64) | 14 | (-134; 68) | ||
| Time since two doses (BNT162b2) | 1470 | ||||||||||||
| Unvaccinated [ref] | 1300 | 112050 | 90 | 34 | 124 | ||||||||
| 14d - 89d from 2nd dose | 732 | 49837 | 9 | 1 | 10 | 0.21 | (0.1; 0.44) | 79 | (56; 90) | 82 | (63; 91) | ||
| 90d-179d from 2nd dose | 485 | 18572 | 11 | 4 | 15 | 0.71 | (0.40; 1.24) | 29 | (-24; 60) | 52 | (13; 73) | ||
| ≥180d from 2nd dose | 151 | 4286 | 5 | 1 | 6 | 0.95 | (0.37; 2.48) | 5 | (-148; 63) | 40 | (-55; 77) | ||
| Time since two doses (BBIBP-CorV) | 1337 | ||||||||||||
| Unvaccinated [ref] | 1300 | 112050 | 90 | 34 | 124 | ||||||||
| 14d - 89d from 2nd dose | 227 | 14894 | 13 | 5 | 18 | 0.85 | (0.49; 1.50) | 15 | (-50; 51) | 36 | (-10; 63) | ||
| 90d-179d from 2nd dose | 132 | 6108 | 5 | 1 | 6 | 0.76 | (0.30; 1.91) | 24 | (-91; 70) | 57 | (-9; 83) | ||
| Delta period | Time since two doses (all vaccines) | 1556 | |||||||||||
| Unvaccinated [ref] | 1162 | 72917 | 67 | 25 | 92 | ||||||||
| 14d - 89d from 2nd dose | 1043 | 61860 | 25 | 7 | 32 | 0.47 | (0.30; 0.75) | 53 | (25; 70) | 54 | (28; 71) | ||
| 90d-179d from 2nd dose | 715 | 30230 | 19 | 7 | 26 | 0.74 | (0.46; 1.21) | 26 | (-21; 54) | 40 | (4; 62) | ||
| ≥180d from 2nd dose | 189 | 4661 | 5 | 1 | 6 | 1 | (0.38; 2.60) | -0 | (-160; 62) | 14 | (-130; 68) | ||
| Time since two doses (BNT162b2) | 1371 | ||||||||||||
| Unvaccinated [ref] | 1162 | 72917 | 67 | 25 | 92 | ||||||||
| 14d - 89d from 2nd dose | 708 | 41088 | 7 | 1 | 8 | 0.21 | (0.09; 0.49) | 79 | (51; 91) | 81 | (56; 91) | ||
| 90d-179d from 2nd dose | 489 | 18631 | 11 | 4 | 15 | 0.77 | (0.44; 1.37) | 23 | (-37; 56) | 38 | (-9; 65) | ||
| ≥180d from 2nd dose | 154 | 4390 | 5 | 1 | 6 | 1.03 | (0.39; 2.72) | -3 | (-172; 61) | 6 | (-151;65) | ||
| Time since two doses (BBIBP-CorV) | 1250 | ||||||||||||
| Unvaccinated [ref] | 1161 | 72906 | 67 | 25 | 92 | ||||||||
| 14d - 89d from 2nd dose | 227 | 13979 | 13 | 5 | 18 | 0.91 | (0.52; 1.59) | 9 | (-59; 48) | 32 | (-21; 61) | ||
| 90d-179d from 2nd dose | 132 | 6108 | 5 | 1 | 6 | 0.75 | (0.30; 1.91) | 25 | (-91; 70) | 57 | (-12; 83) | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated